Your browser doesn't support javascript.
loading
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Gallois, Claire; Shi, Qian; Meyers, Jeffrey P; Iveson, Timothy; Alberts, Steven R; de Gramont, Aimery; Sobrero, Alberto F; Haller, Daniel G; Oki, Eiji; Shields, Anthony Frank; Goldberg, Richard M; Kerr, Rachel; Lonardi, Sara; Yothers, Greg; Kelly, Caroline; Boukovinas, Ioannis; Labianca, Roberto; Sinicrope, Frank A; Souglakos, Ioannis; Yoshino, Takayuki; Meyerhardt, Jeffrey A; André, Thierry; Papamichael, Demetris; Taieb, Julien.
Afiliación
  • Gallois C; Paris-Cité University, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France.
  • Shi Q; Department of Health Science Research, Mayo Clinic, Rochester, MN.
  • Meyers JP; Department of Health Science Research, Mayo Clinic, Rochester, MN.
  • Iveson T; Department of Medical Oncology, University of Southampton, Southampton, United Kingdom.
  • Alberts SR; Department of Oncology, Mayo Clinic, Rochester, MN.
  • de Gramont A; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
  • Sobrero AF; Medical Oncology, IRCCS San Martino IST, Genoa, Italy.
  • Haller DG; Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA.
  • Oki E; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Shields AF; Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Goldberg RM; West Virginia University Cancer Institute and the Mary Babb Randolph Cancer Center, Morgantown, WV.
  • Kerr R; Department of Oncology, Oxford University, Oxford, United Kingdom.
  • Lonardi S; Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IRCCS, Padua, Italy.
  • Yothers G; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA.
  • Kelly C; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Boukovinas I; Bioclinic Thessaloniki Medical Oncology Unit, Thessaloniki, Greece.
  • Labianca R; Ospdale Papa Giovanni XXIII, Bergamo, Italy.
  • Sinicrope FA; Department of Oncology, Mayo Clinic, Rochester, MN.
  • Souglakos I; Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Greece.
  • Yoshino T; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Meyerhardt JA; Dana-Farber Cancer Institute, Boston, MA.
  • André T; Sorbonne Université, Department of Medical Oncology, Hôpital Saint-Antoine, Paris, France.
  • Papamichael D; Division of Medical Oncology, Bank Of Cyprus Oncology Centre, Nicosia, Cyprus.
  • Taieb J; Paris-Cité University, Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France.
J Clin Oncol ; 41(4): 803-815, 2023 02 01.
Article en En | MEDLINE | ID: mdl-36306483
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Colon / Oxaliplatino Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Colon / Oxaliplatino Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos